Dataset Information

IJC Myelodysplastic Syndromes Sequencing Group

ABSTRACT: Data Access Committee EGAC00001000257

OTHER RELATED OMICS DATASETS IN: PRJNA254802

PROVIDER: EGAC00001000257 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Publications

Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Schneider Rebekka K RK Ademà Vera V Heckl Dirk D Järås Marcus M Mallo Mar M Lord Allegra M AM Chu Lisa P LP McConkey Marie E ME Kramann Rafael R Mullally Ann A Bejar Rafael R Solé Francesc F Ebert Benjamin L BL

Cancer cell 20140918 4

The casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the common deleted region for del(5q) myelodysplastic syndrome (MDS). We generated a murine model with conditional inactivation of Csnk1a1 and found that Csnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and a competitive repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell failure. Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitiz ...[more]

PMID: 25242043

Similar Datasets

Project description:The potential mechanism of myelodysplastic syndromes (MDS) progressing to acute myeloid leukemia (AML) remains poorly elucidated. It has been proved that epigenetic alterations play crucial roles in the pathogenesis of cancer progression including MDS. However, fewer studies explored the whole-genome methylation alterations during MDS progression. Reduced representation bisulfite sequencing was conducted in four paired MDS/secondary AML (MDS/sAML) patients and intended to explore the underlying methylation-associated epigenetic drivers in MDS progression. In four paired MDS/sAML patients, cases at sAML stage exhibited significantly increased methylation level as compared with the matched MDS stage. A total of 1090 differentially methylated fragments (DMFs) (441 hypermethylated and 649 hypomethylated) were identified involving in MDS pathogenesis, whereas 103 DMFs (96 hypermethylated and 7 hypomethylated) were involved in MDS progression. Targeted bisulfite sequencing further identified that aberrant GFRA1, IRX1, NPY, and ZNF300 methylation were frequent events in an additional group of de novo MDS and AML patients, of which only ZNF300 methylation was associated with ZNF300 expression. Subsequently, ZNF300 hypermethylation in larger cohorts of de novo MDS and AML patients was confirmed by real-time quantitative methylation-specific PCR. It was illustrated that ZNF300 methylation could act as a potential biomarker for the diagnosis and prognosis in MDS and AML patients. Functional experiments demonstrated the anti-proliferative and pro-apoptotic role of ZNF300 overexpression in MDS-derived AML cell-line SKM-1. Collectively, genome-wide DNA hypermethylation were frequent events during MDS progression. Among these changes, ZNF300 methylation, a regulator of ZNF300 expression, acted as an epigenetic driver in MDS progression. These findings provided a theoretical basis for the usage of demethylation drugs in MDS patients against disease progression.

Dataset Information

IJC Myelodysplastic Syndromes Sequencing Group

Publications

Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets